Subject:
- Active Sustance: Efgartigimod alfa
- Name: Vyvgart®
- Therapeutic area: Myasthenia Gravis
- Pharmaceutical company: Argenx Germany GmbH
Time table:
- Start: 01.09.2022
- Publication of assessment: 01.12.2022
- End of public hearing: 22.12.2022
- Final decision by G-BA: middle of February 2023
Comparative therapy:
- No comparative therapy due to orphan drug designation